Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators

Bibliography

• Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol 2011;31(5):986-1000
   PubMed Web of Science ®Google Scholar
• Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev 2011;63(3):471-538
   PubMed Web of Science ®Google Scholar
• Cathcart M, O'Byrne KJ, Reynolds JV, COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta BBARev Cancer 2012;1825(1):49-63
   PubMed Web of Science ®Google Scholar
• Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006;66(20):9794-7
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Watanabe R, Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 2011;52(5):266-9
   PubMed Web of Science ®Google Scholar
• Honda T, Tokura Y, Miyachi Y, Kabashima K. Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology. Curr Drug Targets 2010;11(12):1605-13
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-8
   PubMed Web of Science ®Google Scholar
• The Procter and Gamble Co. C16 unsaturated FP-selective prostaglandins analogs. US6451859; 2002
   Google Scholar
• The Procter and Gamble Co. Aromatic C16-C20-Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1012137; 2002
   Google Scholar
• The Procter and Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists. US6444840; 2002
   Google Scholar
• The Procter and Gamble Co. C16 unsaturated FP-selective prostaglandins analogs. US200237913; 2002
   Google Scholar
• Duke University. Aromatic C 16?-C 20?-Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1012136; 2004
   Google Scholar
• Duke University. Aromatic C16-C20-Substituted Tetrahydro Prostaglandins Useful AS FP Agonists. EP1021402; 2005
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. FP Receptor Agonist. WO20094990; 2009
   Google Scholar
• Applied Research Systems ARS Holding N.V. Thiazolidine carbocamide derivatives as modulators of the prostaglandin F receptor. WO03082278A1; 2003
   Google Scholar
• Polyphor AG. Conformationally Constrained, Fully Synthetic Macrocyclic Compounds. WO201114973; 2011
   Google Scholar
• Polyphor AG. Conformationally Constrained, Fully Synthetic Macrocyclic Compounds. WO201115241; 2011
   Google Scholar
• Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension. US6342524; US2002103255; US6646001; 2002
   Google Scholar
• Alcon Manufacturing, Ltd. 11beta-fluoro 15beta-hydroxy PGF2alpha analogs as FP receptor antagonists. US6441033; 2002
   Google Scholar
• Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther 1999;290(3):1278-84
   PubMed Web of Science ®Google Scholar
• Allergan Sales, Inc. Glaucoma treatments with reduced hyperpigmentation. US200318078; 2003
   Google Scholar
• The Universityof Arizona. Methods For Screening For Substances Which Inhibit FP Prostanoid Receptor. WO200258546; 2002
   Google Scholar
• Medical Research Council. FP Receptor Antagonists Or Pgf2 Alpha Antagonista For Treating Pathological Conditions Of The Uterus. WO200389001; 2003
   Google Scholar
• Duke University. Compositions And Methods For Promoting Nasal Patency And Treating Neurogenic Bladder Using Prostaglandins. WO2010108012A1; 2010
   Google Scholar
• Duke University. Compositions And Methods For Inhibiting Hair Growth. WO201114649; 2011
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. Hair Growth Agent Composition. WO200723841; 2007
   Google Scholar
• Cayman Chemical Co. Method For Screening Of Prostaglandin Compounds Comprising An Optimal Formulation For The Enhancement Of Hair Growth And The Stimulation Of Follicular Anagen And Formulations Resulting Therefrom. US200988473; 2009
   Google Scholar
• Ursapharm Arzneimittel GmbH. Phosphate-Free Pharmaceutical Composition For The Treatment Of Glaucoma. WO2010130462; 2010
   Google Scholar
• Wilson SM, Sheddan NA, Newton R, Glembycz MA. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release. Mol Pharmacol 2011;79(3):586-95
   PubMed Web of Science ®Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Trisubstituted Furopyrimidines And The Use Thereof As Activators Of The Ip Receptor. WO200962605; 2009
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Substituted Pyrrolotriazines And Their Use. US201128479; 2011
   Google Scholar
• Arena Pharmaceuticals, Inc. Yrazolyl Substituted Carbonic Acid Derivatives As Modulators Of The Prostacyclin (PGI2) Receptor Useful For The Treatment Of Disorders Related Thereto. WO201068242A1; 2010
   Google Scholar
• Arena Pharmaceuticals, Inc. Modulators of the Prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto. WO20100772751; 2010
   Google Scholar
• Arena Pharmaceuticals, Inc. Modulators of the prostacylcin (PGI2) receptor useful for the treatment of disorders related therto. WO2009117095A1; 2009
   Google Scholar
• Novartis AG. IP Receptor Agonist Heterocyclic Compounds. WO20127539; 2012
   Google Scholar
• Syntex (USA) LLC. Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators. US6335459; 2002
   Google Scholar
• Bayer Healthcare AG. Carboxamides Derivatives. WO2003106403; 2003
   Google Scholar
• Bayer Aktiengesellschaft. 2-Naphtamide Derivatives. WO2003106402; 2003
   Google Scholar
• Bayer Healthcare AG. Phenyl Or Heteroaryl Amino Alkane Derivatives As Ip Receptor Antagonist. WO200443926; 2004
   Google Scholar
• Roche bioscience. Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists. US2002169171; 2002
   Google Scholar
• Roche bioscience. Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists. US2002165235; 2002
   Google Scholar
• Syntex (USA) LLC. Substituted-phenyl ketone derivatives as IP antagonists. US6335459; 2002
   Google Scholar
• Roche Palo Alto LLC. Substituted arylamides as IP antagonists. US2004220247; 2004
   Google Scholar
• Actelion Pharmaceuticals Ltd. Therapeutic Compositions Containing Macitentan. WO201018549; 2010
   Google Scholar
• Actelion Pharmaceuticals Ltd. Therapeutic Compositions Containing Macitentan. US2011136818; 2011
   Google Scholar
• The Procter and Gamble Co. Methods for identifying compounds for regulating muscle mass or function using prostanoid IP receptors. US200715214; 2007
   Google Scholar
• Medical Research Council. Substituted Pyrrolotriazines And Their Use Ip Receptor Antagonists For The Treatment Of Pathological Uterine Conditions. WO200471508; 2004
   Google Scholar
• Giannarelli C, Zafar MU, Badimon JJ. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism? Thromb Haemost 2010;104(5):949-54
   PubMed Web of Science ®Google Scholar
• Bal Dit Sollier C, Crassard I, Simoneau G, Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009;28(5):505-13
   PubMed Web of Science ®Google Scholar
• Kabashima K, Murata T, Tanaka H, Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol 2003;4(7):694-701
   PubMed Web of Science ®Google Scholar
• Evolva, Inc. Treatment Of Infections With Tp Receptor Antagonists. WO2011057262A2; 2011
   Google Scholar
• Adir Et Compagnie. Derives de 1,2,3,4-tetrahydronaphtalene, de chromanne et de thiochromanne comme agents antithrombotiques. EP0648741A1; 1993
   Google Scholar
• The Trustees Of The University Of Pennsylvania. Novel Tetrahydronaphthalene Antagonists To The Thromboxane A2 (TP) Receptor. WO2012015944A2; 2012
   Google Scholar
• Thoray Industries, Inc. Benzene Fused Heterocyclic Derivatives Having Thromboxane A2 Receptor Antagonistic Activity And Prostaglandin I2 Agonistic Activity And Application Thereof. US6407096B1; 2002
   Google Scholar
• Les Laboratoires Servier. Use Of An Anti-Atherothrombotic Compound In Obtaining Medicaments Intended For The Treatment Of Vascular Disorders. US20070238785A1; 2007
   Google Scholar
• Musc Foundation For Research Development. Methods For The Treatment Of Cancers. WO2009089098A1; 2009
   Google Scholar
• Thromboxane Inhibitors. Compositions and Methods of Use. US20030050305A1; 2003
   Google Scholar
• B.M.R.A. Corp. B.V. Compositions And Methods Involving The Combination Of A Thromboxane A2 Receptor Antagonist And An Inhibitor Of Cyclooxygenase-1. WO2005016334A1; 2005
   Google Scholar
• Astrazeneca AB. Combinations Comprising A Glucocorticoid Receptor Modulator For The Treatment Of Respiratory Diseases. WO2011061527A1; 2011
   Google Scholar
• Astrazeneca AB. New Combinations For The Treatment Of Asthma. WO2011012897A1; 2011
   Google Scholar
• Philip G, van Adelsberg J, Loeys T, Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol 2009;124(5):942-8; e1-9
   PubMed Web of Science ®Google Scholar
• Applied Research Systems Ars Holding N.V. Pyrrolidin-2-One Derivatives For Use As Dp1 Receptor Agonists. WO200661366; 2006
   Google Scholar
• Aventis Pharmaceuticals, Inc. 2,6-Substituted-4-Monosubstituted Aminopyrimidine As Prostaglandin D2 Receptor Antagonists. WO2006044732A2; 2006
   Google Scholar
• Aventis Pharmaceuticals, Inc. A Combination Of Niacin And A Prostaglandin D2 Receptor Antagonist. WO2008039882A1; 2008
   Google Scholar
• Aventis Pharmaceuticals, Inc. Dihydrogen Phosphate Salt Of A Prostaglandin D2 Receptor Antagonist. US20080194600A1; 2008
   Google Scholar
• Aventis Pharmaceuticals, Inc. Dihydrogen Phosphate Salt Of A Prostaglandin D2 Receptor Antagonist. WO2007047378A2; 2007
   Google Scholar
• Amira Pharmaceuticals, Inc. Substituted Pyrimidines As Prostaglandin D2 Receptor Antagonists. WO2011115940A1; 2011
   Google Scholar
• Amira Pharmaceuticals, Inc. A Substituted Pyrimidine As A Prostaglandin D2 Receptor Antagonist. WO2011115943A1; 2011
   Google Scholar
• Aventis Pharmaceuticals, Inc. 2-Phenyl-Indoles As Prostaglandin D2 Receptor Antagonists. WO2006081343A1; 2006
   Google Scholar
• Sanofi-Aventis. 2-Phenyl Indoles As Prostaglandin D2 Receptor Antagonists. WO2008014186A1; 2008
   Google Scholar
• Merck Frosst Canada & Co. Dihydropyrrolo[1,2-a]indole and tetrahydropyridino[1,2-a]indole derivatives as prostaglandin D2 receptor antagonists. WO02094830A2; 2002
   Google Scholar
• Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentaindole derivatives. WO2005056527A1; 2005
   Google Scholar
• Merck & Co., Inc. Method Of Treating Atherosclerosis, Dyslipidemias And Related Conditions. WO2006026273A2; 2006
   Google Scholar
• Merck & Co., Inc. Method Of Treating Pathological Blushing. WO2006052798A3; 2006
   Google Scholar
• Merck & Co., Inc. Methods Of Treating Pathological Blushing. US20070299122A1; 2007
   Google Scholar
• Merck & Co., Inc. Methods Of Treating Atherosclerosis, Dyslipidemias And Related Disorders. US20040229844A1; 2004
   Google Scholar
• Merck & Co., Inc. Method Of Treating Atherosclerosis, Dyslipidemias And Related Conditions. WO2008097535A2; 2008
   Google Scholar
• Merck & Co., Inc. Methods Of Treating Atherosclerosis, Dyslipidemias And Related Disorders. WO2006089309A2; 2006
   Google Scholar
• Astellas Pharma, Inc. Thiazolylbenzofuran Derivatives As Leukotriene And Prostaglandin D2 Receptor Antagonists. WO2006046683A1; 2006
   Google Scholar
• President And Fellows Of Harvard College. Neurodegenerative Diseases And Methods Of Modeling. US2010130574; 2010
   Google Scholar
• Sturino CF, O'Neill G, Lachance N, Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem 2007;50(4):794-806
   PubMed Web of Science ®Google Scholar
• Hwang, Cheng Shine. Reduction Of Hair Growth. US20050112075A1; 2005
   Google Scholar
• Institut Pasteur De Lille, Institut National De La Sante Et De La Recherche Medicale (INSERM). Use Of Active Compounds Capable Of Modulation The Intracellular Pathway Triggered By The Dp Receptor In Langerhans Cells. WO0245718A1; 2002
   Google Scholar
• Taisho pharmaceutical Co., Ltd. Pharmaceuticals for Xerosis. US20050192357A1; 2005
   Google Scholar
• Schuligoi R, Sturm E, Luschnig P, CRTH2 and D-Type Prostanoid Receptor Antagonists as Novel Therapeutic Agents for Inflammatory Diseases. Pharmacology 2010;85(6):372-82
   PubMed Web of Science ®Google Scholar
• Pettipher R, Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J. Med. Chem 2012;55(7):2915-31
   PubMed Web of Science ®Google Scholar
• Norman P. DP(2) receptor antagonists in development. Expert Opin Investig Drugs 2010;19(8):947-61
   PubMed Web of Science ®Google Scholar
• Barnes N, Pavord I, Chuchalin A, A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42(1):38-48
   PubMed Web of Science ®Google Scholar
• Ulven T, Kostenis E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem 2006;6(13):1427-44
   PubMed Web of Science ®Google Scholar
• Ulven T, Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Patents 2010;20(11):1505-30
   PubMed Web of Science ®Google Scholar
• Norman P. A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Patents 2011;21(12):1931-6
   PubMed Web of Science ®Google Scholar
• Norman P. Evaluation of WO2012078210 - development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist. Expert opin Ther Patents 2012;22(10):1257-61
   PubMed Web of Science ®Google Scholar
• Oxagen Ltd. Compounds Having Crth2 Antagonist Activity. WO200812511; 2008
   Google Scholar
• Oxagen Ltd. Compounds Having CRTH2 Antagonist Activity. US201022613; 2010
   Google Scholar
• Oxagen Ltd. Compounds Having Crth2 Antagonistic Activity. US20100063103; 2010
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO201039982; 2010
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. US2011311483; 2011
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. US20110150834A1; 2011
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators And Preparation Thereof. WO201278210; 2012
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO20129134; 2012
   Google Scholar
• Ironwood Pharmaceuticals, Inc. CRTH2 Modulators. WO20129137; 2012
   Google Scholar
• Merck Frosst Canada Ltd. Indole Derivatives As Crth2 Receptor Antagonists. WO201031182; 2010
   Google Scholar
• Gallant M, Beaulieu C, Berthelette C, Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett 2011;21(1):288-93
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada Ltd. Indole Derivatives As CRTH2 Receptor Antagonists. WO201031183; 2010
   Google Scholar
• Merck Sharp Dohme Corp. Merck Frosst Canada. Indole Derivatives As CRTH2 Receptor Antagonists. WO201099039; 2010
   Google Scholar
• Merck Frosst Canada Ltd. Azaindole Derivatives As CRTH2 Receptor Antagonists. WO201031184; 2010
   Google Scholar
• Wyeth, LLC. Indole Based Receptor Crth2 Antagonists. US2011105509; 2011
   Google Scholar
• Argenta Oral Therapeutics Ltd. Quinoline Derivatives Having Dp And/ Or Crth2 Receptor Activity. WO201040992; 2010
   Google Scholar
• Argenta Oral Therapeutics Ltd. WO2010040989A1; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Aminotetrahydroindazoloacetic Acids. US201016369; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Aminotetrahydroindazoloacetic Acids. US201016368; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Substituted Aminotetralines. US201041713; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Bi-Aryl Aminotetralines. US201041714; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Monoaryl Aminotetralines. US201041760; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Naphthylacetic Acids. US2010125058; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Naphthylacetic Acids. US2010125061; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Naphthylacetic Acids. WO201055005; 2010
   Google Scholar
• Hoffmann-La Roche AG. Naphthylacetic acids. WO2010055004A1; 2010
   Google Scholar
• Boehringer Ingelheim International GmbH. Pyrazole Compounds As CRTH2 Antagonists. US20120028938A1; 2012
   Google Scholar
• Boehringer Ingelheim International GmbH. Pyrazole Compounds As Crth2 Antagonists. WO2011092140A1; 2011
   Google Scholar
• Boehringer Ingelheim International GmbH. New Pharmaceutical Compositions For Treatment Of Respiratory And Gastrointestinal Disorders. WO2010089391A1; 2010
   Google Scholar
• Bayer Healthcare AG. Pyrimidine Derivatives Useful For The Treatment Of Diseases Mediated By CRTH2. WO2004096777A1; 2004
   Google Scholar
• Actimis Pharmaceuticals, Inc. Particulates Of A Crth2 Antagonist. WO2008156780A1; 2008
   Google Scholar
• Actimis Pharmaceuticals, Inc. Amine Salts Of A Crth2 Antagonist. WO2008156781A1; 2008
   Google Scholar
• Boehringer Ingelheim International GmbH. Polymorph Of [4,6-Bis(Dimethylamino)-2-(4-{[4-(Trifluoromethyl)Benzoyl]Amino}Benzyl)Pyrimidin-5-Yl]. WO2011005645A1; 2011
   Google Scholar
• Boehringer Ingelheim International GmbH. Pharmaceutical Composition For Treatment Of Respiratory And Inflammatory Diseases. WO2012013566A1; 2012
   Google Scholar
• Boehringer Ingelheim International GmbH. Pharmaceutical Composition For The Treatment Of Respiratory And Inflammatory Diseases. WO2012013567A1; 2012
   Google Scholar
• Actimis Pharmaceuticals, Inc. Isotopically Enriched Pyrimidin-5-Yl Acetic Acid Derivatives As Crth2 Antagonists. WO2010027448A1; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. Antagonists Of Prostaglandin D2 Receptors. WO2010003120A2; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. Heteroaryl Antagonists Of Prostaglandin D2 Receptors. WO2010039977A2; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. Antagonists Of Prostaglandin D2 Receptors. WO2010003127A2; 2010
   Google Scholar
• Amira Pharmaceuticals. DP2 Antagonist And Uses Thereof. WO2011085033A2; 2011
   Google Scholar
• Amira Pharmaceuticals, Inc. Heteroalkyl Biphenyl Antagonists Of Prostaglandin D2 Receptors. WO2010042652A2; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. DP2 Antagonist And Uses Thereof. US20110034558A1; 2011
   Google Scholar
• Amira Pharmaceuticals, Inc. Cycloalkane[B]Azaindole Antagonists Of Prostaglandin D2 Receptors. WO2010054113A2; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. Cycloalkane[B]Azaindole Antagonists Of Prostaglandin D2 Receptors. WO2010054114A2; 2011
   Google Scholar
• Amira Pharmaceuticals, Inc. Cycloalkane[B]Indole Antagonists Of Prostaglandin D2 Receptors. WO2010008864A2; 2010
   Google Scholar
• Amira Pharmaceuticals, Inc. Dermal Formulations Of Dp2 Receptor Antagonists. WO2011014588A2; 2011
   Google Scholar
• Amira Pharmaceuticals, Inc. Ophthalmic Pharmaceutical Compositions Of Dp2 Receptor Antagonist. WO2011014587A2; 2011
   Google Scholar
• Actelion Pharmaceuticals Ltd. 3-(HETEROARYL-AMINO)-1,2,3,4-Tetrahydro-9h-Carbazole Derivatives And Their Use As Prostaglandin D2 Receptor Modulators. WO2011117798A1; 2011
   Google Scholar
• Shionogi & Co., Ltd. Sulfonamide Derivative Having Pgd2 Receptor Antagonistic Activity. WO2007037187A1; 2007
   Google Scholar
• Astrazeneca AB. Novel Compounds. WO2007052023A2; 2007
   Google Scholar
• Actelion Pharmaceuticals Ltd. 1-Phenyl-Substituted Heterocyclyl Derivatives And Their Use As Prostaglandin D2 Receptor Modulators. WO2012004722A1; 2012
   Google Scholar
• Almirall, S.A. New Pyrazole Derivatives Having Crth2 Antagonistic Behaviour. WO201269175; 2012
   Google Scholar
• Tricyclic Indole-Derived Spiro Derivatives As Crth2 Modulators. WO20116936; 2011
   Google Scholar
• Merck Serono S.A. Phenoxy Acetic Acid Derivatives. WO201092043; 2010
   Google Scholar
• Merck Sharp and Dohme Corp.; Schering Corp. Quinazolinone-Type Compounds As Crth2 Antagonists. WO201251036; 2012
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. Isoquinoline Derivative. EP2377851; 2011
   Google Scholar
• Cara Therapeuticts, Inc. Azabenzimidazolones. WO2010045276A2; 2010
   Google Scholar
• Array Biopharma, Inc. 7-Phenoxychroman carboxylic acid derivatives. WO2010075200A1; 2010
   Google Scholar
• Astrazeneca AB. Combination Of A Benzoxazinone And A Further Agent For Treating Respiratory Diseases. WO2011073662A1; 2011
   Google Scholar
• Astrazeneca AB. Pharmaceutical Product Comprising A P38 Kinase Inhibitor And A Second Active Ingredient. WO2010071583A1; 2011
   Google Scholar
• Astrazeneca AB. Combinations Comprising A Glucocorticoid Receptor Modulator For The Treatment Of Respiratory Diseases. WO2011061527A1; 2011
   Google Scholar
• Astrazeneca AB. Combination Comprising 6-Fluoro-N-((1s,4s)-4-(6-Fluoro-2,4-Dioxo-1-(4'-(Piperazin-1-Yl-Methyl)Biphenyl-3-Yl)-1,2-Dihydropyrido[2,3-D]Pyrimidin-3(4h)-Yl)Cyclohexyl)Imidazo[1,2-A]Pyridine-2-Carboxamide Or A Salt. WO2010004319A1; 2010
   Google Scholar